Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Ruth Plummer.

Newcastle AuthorsTitleYearFull text
Professor Ruth Plummer
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer2022
Professor Ruth Plummer
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer2022
Professor Ruth Plummer
Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers2021
Dr Christopher Bacon
Dr George Petrides
Dr Nicola Leech
Dr Fiona Jenkinson
Professor Ruth Plummer
et al.
A case of malignant hyperlactaemic acidosis appearing on treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.2020
Professor Ruth Plummer
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial2020
Professor Ruth Plummer
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma2020
Dr Nicola Cresti
Professor Ruth Plummer
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine2019
Professor Ruth Plummer
Dr Alastair Greystoke
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours2019
Professor Ruth Plummer
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN Solid Tumor trial2019
Dr Simon Findlay
Dr Jason Gill
Professor Ruth Plummer
Carol De Santis
Dr Chris Plummer
et al.
Chronic cardiovascular toxicity in the older oncology patient population2019
Dr Stamatina Verykiou
Michael Alexander
Dr Noel Edwards
Professor Ruth Plummer
Dr Bill Chaudhry
et al.
Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma2019
Professor Ruth Plummer
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial2019
Professor Ruth Plummer
Professor Steve Wedge
Professor Gareth Veal
A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours2018
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al.
Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase2018
Dr Marina Danilenko
Elaine Stamp
Dr Deborah Stocken
Monique Zangarini
Amy Cranston
et al.
Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib2018
Professor Ruth Plummer
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers2017
Professor Ruth Plummer
Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma2017
Dr Alastair Greystoke
Dr Noor MD Haris
Professor Ruth Plummer
SELECT-3: A phase i study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting2017
Amy Cranston
Dr Deborah Stocken
Elaine Stamp
Professor Ruth Plummer
Professor Sir John Burn
et al.
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.2017
Dr Neil Rajan
Dr Thomas Oliphant
Professor Ruth Plummer
Dr James Langtry
Advanced basal cell carcinomas treated by vismodegib and Mohs micrographic surgery: does neoadjuvant treatment have a role?2016
Professor Ruth Plummer
Professor Steve Wedge
Clinical development of new drug-radiotherapy combinations2016
Dr Rachel Pearson
Professor Peter Thelwall
Jim Snell
Dr Piotr Pieniazek
Professor Rakesh Heer
et al.
Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study2016
Dr Rachel Pearson
Professor Peter Thelwall
Jim Snell
Dr Piotr Pieniazek
Professor Rakesh Heer
et al.
Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study2016
Barry Dent
Laura Ogle
Dr Rachel O'Donnell
Dr Ujjal Mallick
Professor Nicola Curtin
et al.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers2016
Laura Ogle
Dr James Orr
Dr Catherine Willoughby
Dr Claire Hutton
Dr Stuart McPherson
et al.
Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?2016
Professor Ruth Plummer
Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis2016
Dr Peter Stephens
Professor Ruth Plummer
Professor Nicola Curtin
mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition2016
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
Professor Ruth Plummer
Dr Alastair Greystoke
SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting2016
Professor Ruth Plummer
Sonidegib safety in patients with locally advanced Basal Cell Carcinoma and efficacy based on tumor aggressiveness2016
Professor Ruth Plummer
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma2016
Ashleigh McConnell
Dr Robert Ellis
Professor Ruth Plummer
Professor Penny Lovat
Dr Graeme O'Boyle
et al.
The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma2016
Dr Yvette Drew
Dr Alastair Greystoke
Professor Ruth Plummer
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).2015
Dr Manolo D'Arcangelo
Professor Ruth Plummer
A first-in-human study of intravenous BAL101553, a novel microtobule inhibitor, in patients with advanced solid tumors2015
Professor Ruth Plummer
A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors2015
Professor Ruth Plummer
Dr Alastair Greystoke
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors2015
Professor Ruth Plummer
Ian Daniels
An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients2015
Dr Stamatina Verykiou
Professor Ruth Plummer
Professor Penny Lovat
Contribution of autophagy to the survival of melanoma-initiating CD271-positive subpopulations2015
Professor Ruth Plummer
Dr Jane Margetts
Professor John Lunec
Dr Joyce Nutt
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker2015
Professor Ruth Plummer
Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma2015
Professor Ruth Plummer
Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer2015
Professor Ruth Plummer
Pivotal role of sphingomyelin synthase (SGMS) expression and activity in glioma patient survival presents a potential therapeutic target2015
Professor Ruth Plummer
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma2015
Professor Ruth Plummer
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial2015
Professor Ruth Plummer
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial2015
Barry Dent
Dr Rachel O'Donnell
Laura Ogle
Padmini Ramesh
Nick Hayes
et al.
Detection and characterization of circulating tumor cells by imaging flow cytometry2014
Dr Laura Ogle
Dr David Jamieson
Dr Rachel O'Donnell
Barry Dent
Professor Nicola Curtin
et al.
Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStreamx2014
Professor Ruth Plummer
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma2014
Professor Ruth Plummer
Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study2014
Professor Alan Calvert
Professor Ruth Plummer
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer2014
Professor Ruth Plummer
First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma2014
Professor Ruth Plummer
Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma2014
Dr Neil Rajan
Dr Piotr Pieniazek
Paul Hainsworth
Dr Fiona Douglas
Professor Ruth Plummer
et al.
Mesenteric cysts in Gorlin syndrome: a mimic of metastatic disease2014
Professor Ruth Plummer
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database2014
Professor Ruth Plummer
Dr Nicola Cresti
Dr Yvette Drew
Dr Peter Stephens
Dr Jared Thornton
et al.
Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma2014
Professor Ruth Plummer
Ian Daniels
Phase I trial of ImmunoBody in melanoma patients2014
Professor Ruth Plummer
Poly(ADP-ribose)polymerase (PARP) Inhibitors: From Bench to Bedside2014
Ashleigh McConnell
Dr Robert Ellis
Dr Graeme O'Boyle
Professor Ruth Plummer
Dr Stamatina Verykiou
et al.
Prognostic significance of CXCR4 expression in cutaneous melanoma2014
Professor Ruth Plummer
The HALO study: A phase I-II of the oral HSP90 inhibitor Debio0932 in combination with SOC in first- and second-line therapy of advanced NSCLC2014
James Murray
Huw Thomas
Philip Berry
Suzanne Kyle
Dr Miranda Morton
et al.
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules2014
Dr Yvette Drew
Ajay Gupta
Professor Ruth Plummer
A Phase 1 Study of Oral or Intravenous Rucaparib in Combination in Combination with Platinum-Containing Chemotherapeutic Regimens: Analysis of Patients with Ovarian or Peritoneal Tumors2013
Dr Nicola Cresti
Professor Ruth Plummer
A phase 1 study of oral rucaparib in combination with carboplatin2013
Dr Nicola Cresti
Dr Yvette Drew
Professor Ruth Plummer
A phase I study of oral rucaparib in combination with carboplatin2013
Professor Ruth Plummer
A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors2013
Professor Ruth Plummer
Dr Evan Mulligan
Professor Nicola Curtin
Professor Alan Calvert
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation2013
Professor Ruth Plummer
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma2013
Dr Jane Margetts
Dr Yvette Drew
Dr Peter Stephens
Professor Alan Calvert
Professor Ruth Plummer
et al.
Erratum to: Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013 Doi: 10.1007/s10637-012-9843-5)2013
Dr Graeme O'Boyle
Isabella Swidenbank
Dr Helen Marshall
Catriona Barker
Dr Jane Renwick
et al.
Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD110702013
Professor Ruth Plummer
Inhibitor of ATR (Ataxia Telangiectasia and RAD3 Related) Kinase2013
Professor Ruth Plummer
Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma2013
Professor Ruth Plummer
Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma2013
Dr Jane Margetts
Dr Yvette Drew
Professor Ruth Plummer
Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors2013
Professor Ruth Plummer
Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC)2013
Professor Ruth Plummer
Professor Alan Calvert
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma2013
Professor Ruth Plummer
Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal2013
Dr Ahmed Elattar
Dr Asima Mukhopadhyay
Dr Fadhel Shaheen
Professor Ruth Plummer
Professor Craig Robson
et al.
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer2012
Dr Asima Mukhopadhyay
Professor Ruth Plummer
Dr Ahmed Elattar
Dr San Soo Hoo
Bisha Uzir
et al.
Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival2012
Dr Asima Mukhopadhyay
Professor Ruth Plummer
Dr Ahmed Elattar
Dr San Soo Hoo
Bisha Uzir
et al.
Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival2012
Dr Asima Mukhopadhyay
Professor Ruth Plummer
Dr Ahmed Elattar
Dr San Soo Hoo
Bisha Uzir
et al.
Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival2012
Dr Aiste McCormick
Dr Asima Mukhopadhyay
Professor Ruth Plummer
Professor Nicola Curtin
Professor Richard Edmondson
et al.
Defective homologous recombination in human cancers2012
Dr Britta Vormoor
Sarah Wilkinson
Fiona Harvey
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699)2012
Professor Ruth Plummer
Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging2012
Professor Ruth Plummer
Ipilimumab for advanced melanoma in an expanded access programme (EAP): Ocular, mucosal and acral subtype UK experience2012
Professor Ruth Plummer
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy2012
Professor Ruth Plummer
Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors2012
Dr Nicola Cresti
Professor Ruth Plummer
Pharmacokinetics of eribulin mesilate in combination with capecitabine in patients with advanced/metastatic cancer: Results from a phase IB dose-escalation study2012
Professor Ruth Plummer
Phase Ib dose-escalation study of eribulin in combination with capecitabine in patients with advanced/metastatic cancer2012
Professor Ruth Plummer
Understanding failure of PARP inhibition in the clinic2012
Professor Ruth Plummer
Professor Alan Boddy
Julieann Sludden
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours2011
Professor Ruth Plummer
Professor Hilary Calvert
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors2011
Professor Ruth Plummer
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers2011
Dr Asima Mukhopadhyay
Professor Nicola Curtin
Professor Ruth Plummer
Professor Richard Edmondson
PARP Inhibitors And Epithelial Ovarian Cancer: An Approach To Targeted Chemotherapy And Personalized Medicine2011
Professor Ruth Plummer
Professor Alan Calvert
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas2011
Professor Ruth Plummer
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?2011
Professor Ruth Plummer
Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?2011
Tomasz Zaremba
Huw Thomas
Mike Cole
Dr Sally Coulthard
Professor Ruth Plummer
et al.
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers2011
Professor Ruth Plummer
Targeting DNA damage repair beyond PARP - further drugs or targets in development2011
Dr Fadhel Shaheen
Pawel Znojek
Dr Ann Fisher
Professor Ruth Plummer
Dr Luke Gaughan
et al.
Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer2011
Dr Yvette Drew
Dr Evan Mulligan
Wan Vong
Huw Thomas
Suzanne Kyle
et al.
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA22011
Rachel Daniel
Dr Agata Rozanska
Dr Evan Mulligan
Dr Yvette Drew
Huw Thomas
et al.
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-0146992010
Professor Ruth Plummer
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients [abstract]2010
Tomasz Zaremba
Huw Thomas
Mike Cole
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials2010
Professor Ruth Plummer
Educational Lecture: Mechanisms of DNA damage and repair2010
Professor Ruth Plummer
Encouraging first experiences with PARP inhibitors2010
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Mike Cole
Professor Ruth Plummer
et al.
Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy2010
Dr Fathi Azribi
Dr Nicholas Bown
Dr Petra Dildey
Stephen Clark
Professor Ruth Plummer
et al.
Extraosseous Pericardial Ewing's Sarcoma2010
Professor Ruth Plummer
Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target2010
Dr Peter Stephens
Professor Alan Calvert
Professor Ruth Plummer
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors2010
Professor Ruth Plummer
Radiotherapy Research Priorities for the UK2010
Professor Alan Calvert
Professor Ruth Plummer
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours2010
Dr Yvette Drew
Professor Ruth Plummer
The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer2010
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Amy Quinn
Professor Alan Calvert
et al.
The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy2010
Dr Agata Rozanska
Dr Evan Mulligan
Huw Thomas
Deborah Castelbuono
Professor Deborah Tweddle
et al.
[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-0146992009
Dr Evan Mulligan
Tomasz Zaremba
Dr Yvette Drew
Professor Ruth Plummer
Professor Nicola Curtin
et al.
[abstract] Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes2009
Dr Evan Mulligan
Professor Nicola Curtin
Professor Ruth Plummer
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines2009
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Professor Ruth Plummer
Professor Alan Calvert
et al.
Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis2009
Dr Agata Rozanska
Huw Thomas
Dr Evan Mulligan
Dr Yvette Drew
Deborah Castelbuono
et al.
Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma2009
Professor Ruth Plummer
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy2009
Professor Ruth Plummer
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy2009
Professor Ruth Plummer
Ipilmumab in pretreated metastatic uveal melanoma patients: Safety and clinical efficacy2009
Dr Yvette Drew
Professor Ruth Plummer
PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications2009
Professor Ruth Plummer
Melanie Griffin
Dr Sally Coulthard
Julieann Sludden
Professor Alan Calvert
et al.
Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors2009
Professor Ruth Plummer
Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM)2009
Tomasz Zaremba
Professor Ruth Plummer
Dr Sally Coulthard
Mike Cole
Professor Nicola Curtin
et al.
Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in a panel of human tumor cell lines [abstract]2009
Tomasz Zaremba
Mike Cole
Dr Sally Coulthard
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines2009
Professor Ruth Plummer
Professor Alan Boddy
Melanie Griffin
Dr Mark Verrill
A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies2008
Professor Ruth Plummer
CYP-activated prodrugs as chemotherapeutics2008
Dr Yvette Drew
Suzanne Kyle
Professor Richard Edmondson
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? [abstract]2008
Professor Ruth Plummer
Professor Alan Calvert
Mechanisms of chemoresistance to alkylating agents in malignant glioma.2008
Professor Ruth Plummer
Professor Alan Calvert
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)2008
Dr Christopher Jones
Professor Ruth Plummer
PARP inhibitors and cancer therapy - early results and potential applications2008
Professor Alan Calvert
Professor Ruth Plummer
Professor Nicola Curtin
Professor Richard Edmondson
Dr Yvette Drew
et al.
PARP inhibitors in cancer treatment2008
Professor Alan Calvert
Professor Nicola Curtin
Professor Ruth Plummer
PARP inhibitors in ovarian cancer2008
Professor Ruth Plummer
Phase I and II clinical trials of the potent intravenous PARP inhibitor, AG0146992008
Professor Ruth Plummer
Professor Alan Calvert
Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma2008
Professor Ruth Plummer
Dr Christopher Jones
Professor Nicola Curtin
Professor Alan Boddy
Professor Herbie Newell
et al.
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors2008
Tomasz Zaremba
Mike Cole
Dr Sally Coulthard
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Poly(ADP-ribose) polymerase-1 (PARP-1) genomics in relation to activity in healthy volunteers and cancer patients2008
Professor Alan Calvert
Professor Ruth Plummer
The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials2008
Professor Ruth Plummer
Professor Alan Calvert
[Meeting Abstract] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI2007
Professor Ruth Plummer
Rebecca Perrett
Professor Alan Calvert
A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor2007
Professor Alan Calvert
Dr Fathi Azribi
Rebecca Perrett
Professor Ruth Plummer
Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR2007
Professor Ruth Plummer
Dr Louise Li
Rebecca Perrett
Professor Alan Calvert
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers2007
Professor Ruth Plummer
Professor Alan Calvert
Targeting poly(ADP-ribose) polymerase: A two-armed strategy for cancer therapy2007
Professor Ruth Plummer
Rebecca Perrett
Professor Alan Calvert
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours2006
Professor Ruth Plummer
Professor Alan Calvert
First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)2006
Professor Ruth Plummer
Inhibition of poly(ADP-ribose) polymerase in cancer2006
Professor Ruth Plummer
Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors2006
Professor Ruth Plummer
Dr Louise Li
Rebecca Perrett
Professor Alan Calvert
Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR2006
Professor Ruth Plummer
Professor Alan Calvert
Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors2006
Professor Ruth Plummer
Poly(ADP-ribose) polymerase inhibition and its potential use in malignant melanoma2006
Professor Ruth Plummer
Poly(ADPribose)polymerase inhibitors - the current clinical status2006
Professor Ruth Plummer
Rebecca Perrett
Professor Alan Calvert
A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors2005
Mark Leslie
Julieann Sludden
Professor Ruth Plummer
Dr Alastair Greystoke
Professor Alan Calvert
et al.
A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.2005
Professor Alan Boddy
Professor Ruth Plummer
Julieann Sludden
Melanie Griffin
Dr Mark Verrill
et al.
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules2005
Professor Ruth Plummer
Professor Alan Boddy
Professor Nicola Curtin
Professor Herbie Newell
Lynsey Robson
et al.
Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide2005
Professor Ruth Plummer
Dr Christopher Jones
Lynsey Robson
Professor Alan Calvert
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors2005
Professor Ruth Plummer
Professor Alan Calvert
Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies2005
Dr Ashraf Azzabi
Dr Andrew Hughes
Dr Paula Calvert
Professor Ruth Plummer
Melanie Griffin
et al.
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations2005
Professor Ruth Plummer
Dr Christopher Jones
Professor Alan Boddy
Professor Alan Calvert
Professor Herbie Newell
et al.
Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-12005
Professor Alan Calvert
Professor Ruth Plummer
The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results.2005
Professor Ruth Plummer
Dr Andrew Hughes
Dr Martin Highley
Dr Sathyarathna Gokul
Professor Alan Calvert
et al.
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor2003
Professor Ruth Plummer
Dr Mark Verrill
Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced malignancies2002
Professor Ruth Plummer
Dr Paula Calvert
Professor Alan Calvert
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies2002
Dr Andrew Hughes
Dr Paula Calvert
Dr Ashraf Azzabi
Professor Ruth Plummer
Melanie Griffin
et al.
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma2002
Dr Andrew Hughes
Dr Ashraf Azzabi
Professor Ruth Plummer
Dr Jane Margetts
Kevin Fishwick
et al.
A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate).2001
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer2001
Dr Paula Calvert
Dr Ashraf Azzabi
Dr Andrew Hughes
Professor Ruth Plummer
Angela Robinson
et al.
A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours.2000
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer2000
Dr Martin Highley
Professor Ruth Plummer
Phase I study of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies1999
Professor Ruth Plummer
Professor Alan Calvert
Dr Martin Highley
Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks1999